DEFINIUM THERAPEUTICS INC (DFTX) competitors & alternatives
Health Care · NASDAQ
DEFINIUM THERAPEUTICS INC (DFTX)'s top competitors and alternatives — its most similar public companies — include COMPASS INC CLASS A (COMP), CONTINEUM THERAPEUTICS INC CLASS A (CTNM), LIFESTANCE HEALTH GROUP INC (LFST), VANDA PHARMACEUTICALS INC (VNDA), Axsome Therapeutics, Inc. (AXSM), ATAIBECKLEY INC (ATAI), XENON PHARMACEUTICALS INC (XENE), NRX Pharmaceuticals, Inc. (NRXP), ALKERMES (ALKS), LB PHARMACEUTICALS INC (LBRX), TONIX PHARMACEUTICALS HOLDING CORP (TNXP) and INDIVIOR PHARMACEUTICALS INC (INDV). These are DEFINIUM THERAPEUTICS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top DFTX competitors & alternatives
-
COMPASS INC CLASS ACOMPReal Estate
Global real estate services platform combining owned-brokerage brands (Compass, Coldwell Banker, Corcoran, Sotheby's International Realty) with a large…
$11.26 (as of 2026-07-22) · market cap $8.5B
-
CONTINEUM THERAPEUTICS INC CLASS ACTNMHealth Care
A clinical-stage biopharmaceutical company developing small-molecule therapies targeting neuroimmune and inflammatory indications, with lead programs PIPE-791…
$14.73 (as of 2026-07-22) · market cap $518M
-
LIFESTANCE HEALTH GROUP INCLFSTHealth Care
LifeStance is a large-scale, tech-enabled outpatient mental health platform combining virtual and in-person care across 33 states with over 8,000 clinicians to…
$11.01 (as of 2026-07-22) · market cap $4.3B
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
Axsome Therapeutics, Inc.AXSMHealth Care
A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel…
$239.62 (as of 2026-07-22) · market cap $12.3B
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
XENON PHARMACEUTICALS INCXENEHealth Care
A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and…
$66.18 (as of 2026-07-22) · market cap $6.7B
-
NRX Pharmaceuticals, Inc.NRXPHealth Care
Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three…
$4.48 (as of 2026-07-22) · market cap $186M
-
ALKERMESALKSHealth Care
Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance…
$52.58 (as of 2026-07-22) · market cap $8.8B
-
LB PHARMACEUTICALS INCLBRXHealth Care
LB Pharmaceuticals is a late-stage biopharmaceutical firm developing LB-102, a novel benzamide candidate aimed at becoming a first-in-class treatment for…
$35.84 (as of 2026-07-22) · market cap $921M
-
TONIX PHARMACEUTICALS HOLDING CORPTNXPHealth Care
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS,…
$10.59 (as of 2026-07-22) · market cap $184M
-
INDIVIOR PHARMACEUTICALS INCINDVHealth Care
Indivior is a specialty pharmaceutical company dedicated to developing and marketing treatments for substance use disorders and mental health conditions,…
$40.45 (as of 2026-07-22) · market cap $4.9B
Not quite? Describe exactly what you want →
Peers are DEFINIUM THERAPEUTICS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: DEFINIUM THERAPEUTICS INC (DFTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.